产品
编 号：F497677
分子式：C22H26N6O2
分子量：406.48
分子式：C22H26N6O2
分子量：406.48
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 885220-61-1
产品详情
生物活性：
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.
体内研究：
Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316?311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hocanalysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6?h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline).
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.
体内研究：
Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316?311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hocanalysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6?h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备